Topical Minoxidil Hair and Skin Changes: What the Clinical Evidence Actually Shows

What the trials show for hair

Topical minoxidil is an over-the-counter regrowth product. The 2% solution was approved in 1988 and switched to over-the-counter status in 1996 [6]. Topical minoxidil is also sold as a 5% solution and a 5% foam.

A head-to-head trial in men randomized 393 men aged 18 to 49 to 5% solution (n=157), 2% solution (n=158) or placebo (n=78), applied twice daily for 48 weeks [1]. The 5% solution was significantly superior to both 2% and placebo on change from baseline in nonvellus hair count, on patient rating of scalp coverage and treatment benefit, and on investigator rating of scalp coverage, and the hair count data show that response came earlier with 5% than with 2% [1]. Increased pruritus and local irritation occurred with the 5% solution [1].

In women, a 48-week trial of 381 women aged 18 to 49 (5% solution, n=153; 2% solution, n=154; placebo, n=74) found 5% solution superior to placebo on all three primary measures: nonvellus hair count, patient assessment and investigator assessment [2]. The 5% group was also statistically superior to the 2% group on patient-rated treatment benefit at week 48 [2].

The 5% foam was tested separately. A 16-week double-blind trial in 352 men aged 18 to 49 found a statistically significant increase in hair counts with foam versus placebo (P<.0001); 143 men continued into a 52-week open-label safety phase, and no efficacy data were collected beyond 16 weeks [7]. In 113 women, once-daily 5% foam was noninferior to twice-daily 2% solution for target-area hair count and hair width over 24 weeks, and produced significantly less local intolerance (P=.046), mainly less pruritus and dandruff [8]. Participants in that trial were not blinded to treatment [8].

What minoxidil does inside the follicle

In organ-cultured mouse vibrissa follicles, minoxidil sulfate was 14 times more potent than minoxidil at stimulating cysteine incorporation into hair shafts. Blocking the sulfation step stopped minoxidil from working, while minoxidil sulfate still worked, which led the authors to conclude that the sulfated metabolite directly affects hair follicles [5].

In human hair dermal papilla cells, minoxidil raised vascular endothelial growth factor (VEGF) mRNA and protein in a dose-dependent way; cells treated with 24 micromol/L expressed six times more VEGF mRNA than controls [9].

Skin changes on the scalp

Irritation is the skin signal the trials report most consistently. In the 48-week trial in men, the 5% solution produced more pruritus and local irritation [1]. Across 24 weeks in 113 women, once-daily 5% foam caused less local intolerance than twice-daily 2% solution (P=.046), mainly less pruritus and dandruff [8], and the foam vehicle contains no propylene glycol [7].

Patch testing points at the vehicle more than the drug. Among patients with scalp itching and scaling who were patch tested, propylene glycol was the contactant in a majority of cases, not minoxidil itself [10]. The authors suggest that many of these patients may be candidates for alternative formulations using other solvents, but note that patch testing does not ensure a compounded preparation will be tolerated, and that patients found to be allergic to minoxidil itself are no longer candidates for topical minoxidil in any form [10].

The label lists a red, inflamed, infected, irritated or painful scalp, or use of other medicines on the scalp, among the conditions the product is not for, and lists scalp irritation or redness among the reasons for stopping it [3][4].

Unwanted facial hair and hair color

Both the men's 5% solution label and the women's 5% foam label list unwanted facial hair growth among the reasons for stopping the product [3][4]. The labels also state that some people have experienced changes in hair color and/or texture while using the product [3].

How much minoxidil reaches the blood

A 1985 absorption study applied radiolabeled 1% and 5% solutions to bald scalp in 12 adult men across nine applications [11]. Urinary excretion of radioactivity averaged 1.6% to 3.9% of the applied dose, 41% to 45% was recovered from the skin surface and from scalp and pillowcase washes, and the authors estimated that systemic doses of 2.4 to 5.4 mg/day could be anticipated if the product were applied to the entire scalp [11].

The men's 5% label names heart disease as a caution and lists chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, and swelling of the hands or feet as warning symptoms [3].

Oral minoxidil tablets are a separate prescription product approved only for severe hypertension [12]. In a meta-analysis of uncontrolled studies of off-label oral minoxidil at 5 mg/day or less for hair loss, systolic blood pressure changed by a mean difference of -0.13 mm Hg (95% CI -2.67 to 2.41), heart rate rose 2.67 beats/min (95% CI 0.34 to 5.01), and hypotensive symptoms occurred in 119 patients (5.0%) [13].

Where the label says to apply it, and how often

The men's 5% solution label directs users to apply 1 mL with the dropper twice daily, directly onto the scalp in the hair loss area, for the top of the scalp (vertex) only; the label is for men only and says the product is not intended for frontal baldness or a receding hairline [3]. It says results may occur at 2 months with twice-daily use and some men may need at least 4 months, that using more or more often will not improve results, and that continued use is necessary to increase and keep hair regrowth, or hair loss will begin again [3].

The women's 5% foam label directs users to apply half a capful once daily directly to the scalp in the hair loss area, massage it into the scalp with the fingers, then wash hands well [4]. The label says results may occur at 3 months with once-daily use, and that some women may need to use the product once a day for at least 6 months [4]. The same continued-use statement applies [4].

The men's 5% solution label says flammable, keep away from fire or flame [3]. The women's 5% foam label says extremely flammable, avoid fire, flame or smoking during and immediately following application [4]. In January 2026 the FDA approved label additions telling users to keep the product out of reach of pets and to avoid contact between children and application sites [14].